The Favorable Impact of HBcAb Positive Grafts on Liver Transplantation for HBV-related HCC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6924 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The utilization of marginal grafts may help alleviate the demand mismatch. However, strategies to optimize the use of hepatitis B core antibody (HBcAb) positive grafts still requires further investigation. This study aims to investigate possible interactions between HBcAb positive grafts, HCC and HBV-related diseases, and long-term patient and graft survival. The study retrospectively analyzed patients undergoing liver transplantation in 8 centers between January 2015 and December 2020.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detecting Occult HBV Infection in Liver Donors Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc)

NCT04199819

Occult Hepatitis B Liver Transplant; Complications

UNKNOWN NA

HBV Vaccine in Anti-core Positive Donors After LT

NCT04442841

Hepatitis B Reactivation

UNKNOWN PHASE2

A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

NCT05686759

Hepatitis B

RECRUITING PHASE3

HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102

NCT03519113

Hepatitis B Infection

UNKNOWN PHASE2/PHASE3

Transplantation Using Hepatitis C Positive Donors, A Safety Trial

NCT04017338

Lung Transplant Infection Heart Transplant Infection Kidney Transplant Infection +2 more

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This retrospective observational study included patients who underwent liver transplantation between January 2015 and December 2020 from 8 transplant centers in China, including the First Affiliated Hospital, Zhejiang University School of Medicine, Shulan (Hangzhou) Hospital, the Affiliated Hospital of Qingdao University, the Third Affiliated Hospital of Sun Yat-sen University, West China Hospital of Sichuan University, HuaShan Hospital of Fudan University, Beijing Chaoyang Hospital of Capital Medical University, and the Second Xiangya Hospital of Central South University. Demographic and clinicopathological data of these patients were extracted from the prospectively maintained China Liver Transplant Registry (CLTR) database. The exclusion criteria were as follows: (1) re-transplantation, combined organ transplantation or living donor liver transplantation; (2) intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma; (3) HBsAg positive graft; and (4) missing of baseline data. Patients who were lost to follow-up were also excluded.

Statistical analysis was performed with GraphPad Prism (Version 9), IBM SPSS Statistics (Version 26) and R version 4.3.1 (R Foundation). Regarding the initial demographic data, continuous variables were depicted as medians (IQR: Inter-Quartile Range) and analyzed for differences with the Mann-Whitney U test. Categorical variables were contrasted through the application of the chi-squared test. Cumulative patient survival, graft survival, recurrence-free survival and recurrence rate were analyzed by the Kaplan-Meier method and compared with the log-rank test. To lessen the impact of potential confounders and selection bias, propensity score matching (PSM) was implemented to form comparable groups. Unbalanced variables were entered into the 1:1 matching model. Cox proportional hazard models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for the relationship between variables and the event of interest. Univariate analyses were performed to identify the potential risk factors for patient survival, graft survival and recurrence-free survival in each group. Variables (P\<0.10) were included in the backward stepwise multivariate analyses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HBcAb negative group

Liver transplant recipients with HBcAb negative grafts

No Interventions

Intervention Type OTHER

HBcAb positive group

Liver transplant recipients with HBcAb positive grafts

No Interventions

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No Interventions

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1) primary transplantation; (2) complete baseline data.

Exclusion Criteria

* (1) re-transplantation, combined organ transplantation or living donor liver transplantation; (2) intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma; (3) HBsAg positive graft; and (4) missing of baseline data. Patients who were lost to follow-up were also excluded.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No